162046-59-5

Basic information

• Product Name: 2-CHLORO-4-(CHLOROMETHYL)-6-METHYLPYRIDINE
• Synonyms: 2-CHLORO-4-(CHLOROMETHYL)-6-METHYLPYRIDINE
• CAS NO: 162046-59-5
• Molecular Formula: C7H7Cl2N
• Molecular Weight: 176.04318
• Mol File: 162046-59-5.mol

Chemical Properties

• Boiling Point: 258.8±35.0 °C(Predicted)
• Appearance: /
• Density: 1.270±0.06 g/cm3(Predicted)
• PKA: 1.09±0.10(Predicted)
• CAS DataBase Reference: 2-CHLORO-4-(CHLOROMETHYL)-6-METHYLPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-4-(CHLOROMETHYL)-6-METHYLPYRIDINE(162046-59-5)
• EPA Substance Registry System: 2-CHLORO-4-(CHLOROMETHYL)-6-METHYLPYRIDINE(162046-59-5)

Safety Data

• Hazardous Substances Data: 162046-59-5(Hazardous Substances Data)

Upstream product

• 25462-85-5 2-chloro-6-methylpyridine-4-carboxylic acid 
• 152815-18-4 (2-chloro-6-methyl-pyridin-4-yl)-methanol 

Downstream Products

• 1610358-63-8 (rac)-5-bromo-N-[5-fluoro-4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl]-6-methyl-4-[(S-methylsulfonimidoyl)methyl]pyridin-2-amine 
• 1610358-61-6 (rac)-5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{6-methyl-4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine 
• 1610359-07-3 (rac)-N-{[(3-bromo-6-{[5-fluoro-4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl]amino}-2-methylpyridin-4-yl)methyl](methyl)-λ⁴-sulfanylidene}-2,2,2-trifluoroacetamide 
• 1610359-35-7 (rac)-2,2,2-trifluoro-N-{[(2-{[5-fluoro-4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl]amino}-6-methylpyridin-4-yl)methyl](methyl)-λ⁴-sulfanylidene}acetamide 
• 1602486-09-8 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{6-methyl-4-[(methylsulfanyl)methyl]pyridin-2-yl}pyridin-2-amine 
• 1610462-76-4 (R)-6-(4-fluoro-2-methoxyphenyl)-N-{6-methyl-4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyrimidin-4-amine 
• 1610462-77-5 (S)-6-(4-fluoro-2-methoxyphenyl)-N-{6-methyl-4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyrimidin-4-amine 
• 1610462-75-3 (rac)-6-(4-fluoro-2-methoxyphenyl)-N-{6-methyl-4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyrimidin-4-amine 
• 1610462-86-6 (rac)-2,2,2-trifluoro-N-{[(2-{[6-(4-fluoro-2-methoxyphenyl)pyrimidin-4-yl]amino}-6-methylpyridin-4-yl)methyl](methyl)-λ⁴-sulfanylidene}acetamide 
• 1603922-87-7 6-(4-fluoro-2-methoxyphenyl)-N-{6-methyl-4-[(methylsulfonyl)methyl]pyridin-2-yl}pyrimidin-4-amine 
• 1603923-09-6 C₁₉H₁₉FN₄OS 

Relevant articles and documents

CGRP RECEPTOR ANTAGONISTS

The present invention provides a compound of Formula II: (II) or a pharmaceutically acceptable salt thereof.

CGRP RECEPTOR ANTAGONISTS

The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.

N-(PYRIDIN-2-YL)PYRIMIDIN-4-AMINE DERIVATIVES CONTAINING A SULFONE GROUP

The present invention relates to N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorder

N-(PYRIDIN-2-YL)PYRIMIDIN-4-AMINE DERIVATIVES CONTAINING A SULFOXIMINE GROUP

The present invention relates to disubstituted N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfoximine group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/ or prophylaxis of disorders, in particular of hyper- proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).

5-FLUORO-N-(PYRIDIN-2-YL)PYRIDIN-2-AMINE DERIVATIVES CONTAINING A SULFOXIMINE GROUP

The present invention relates to 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).

HETEROCYCLIC ANTI-MIGRAINE AGENTS

The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras